Alnylam Pharmaceuticals

Email address and contacts

Alnylam Pharmaceuticals company description

To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. We now have three additional medicines on the market: GIVLAARI (givosiran), OXLUMO (lumasiran) and LEQVIO (inclisiran) in partnership with Novartis). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,700 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer 3 years in a row ('19-'21), a Boston Globe Top Place to Work 7x in a row ('15-'21) and one of Fast Company's Best Workplaces for Innovators for 2021. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy

Key Employees

?
************
GVP QA Manager
Find Email
D
Dimah Al Azawi Mpharmsci
Senior Regulatory Affairs Consultant
K
Kendra Wade
Travel and Expense Administrator
K
Kanita Howard
Business Account Executive
B
Breana Lambert
Senior QA Associate, R&D/PV
J
Jolanda Van Giesen Meyer
Medical Science Liaison Rare Diseases a.i.
M
Micah Gauthier
Research Associate II
Sign up to open these and 5 more emails in Alnylam Pharmaceuticals
Message error line

Alnylam Pharmaceuticals competitors and alternatives

Miltenyi Biotec
Biotechnology
2102 employees
AGC Biologics
Biotechnology
2095 employees
The Jackson Laboratory
Biotechnology
1901 employees
Foundation Medicine
Biotechnology
1812 employees
Kemin Industries
Biotechnology
1645 employees
Tempus Labs, Inc.
Biotechnology
1564 employees
View all competitors

Recently updated team members of Alnylam Pharmaceuticals

K
Kelley Boucher
Chief Human Resources Officer
P
PJ Arnold
Medical Science Liaison
A
Akanksha Mittal
Senior Director, Rare Disease Lead, US Medical Affairs
H
Heather Swech
Senior Director, Global Patient Discovery CoE
P
Paul Medeiros
Associate Director, Manufacturing
G
Gilles Bertrand
Sr Dir., Strategy & Planning, International
View all employees

GetProspect Email Finder

Retrieve thousands of email addresses in single click without leaving your current tab. Download for free now!

100 Free emails every month

Add to Chrome

400+ reviews 50,000+ users

Ready to get started?

Try GetProspect email finder for free, and explore all the tools you need to scale your business

Real data
No credit card needed
Leave any time
Find Emails